OBJECTIVES: The Gynecologic Oncology Group (GOG) performed a randomized phase II study to determine the antitumor activity and toxicity of two different schedules of bryostatin-1 administration in patients with recurrent or persistent platinum-sensitive epithelial ovarian cancer or primary peritoneal carcinoma. METHODS:Eligible patients were randomized to receive either bryostatin-1 25 microg/m2 as a 1h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I) or bryostatin-1 120 microg/m2 as a 72 h continuous infusion every 2 weeks (Regimen II). RESULTS:Fifty-five patients were enrolled on this study. There was one durable response among 27 eligible patients (response rate=3.7%) on Regimen II and no responses in the 27 eligible patients on Regimen I. Nineteen patients (eleven on Regimen I and eight on Regimen II) had stable disease. The most common adverse event was myalgia, with 12 of 27 patients (44%) on each regimen experiencing some degree of myalgia. There were no other significant toxicities on either treatment arm. CONCLUSIONS: Both of these schedules and doses of bryostatin-1 are inactive as single agents in previously treated epithelial ovarian cancer.
RCT Entities:
OBJECTIVES: The Gynecologic Oncology Group (GOG) performed a randomized phase II study to determine the antitumor activity and toxicity of two different schedules of bryostatin-1 administration in patients with recurrent or persistent platinum-sensitive epithelial ovarian cancer or primary peritoneal carcinoma. METHODS: Eligible patients were randomized to receive either bryostatin-1 25 microg/m2 as a 1h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I) or bryostatin-1 120 microg/m2 as a 72 h continuous infusion every 2 weeks (Regimen II). RESULTS: Fifty-five patients were enrolled on this study. There was one durable response among 27 eligible patients (response rate=3.7%) on Regimen II and no responses in the 27 eligible patients on Regimen I. Nineteen patients (eleven on Regimen I and eight on Regimen II) had stable disease. The most common adverse event was myalgia, with 12 of 27 patients (44%) on each regimen experiencing some degree of myalgia. There were no other significant toxicities on either treatment arm. CONCLUSIONS: Both of these schedules and doses of bryostatin-1 are inactive as single agents in previously treated epithelial ovarian cancer.
Authors: K Zaugg; S Rocha; H Resch; I Hegyi; C Oehler; C Glanzmann; D Fabbro; S Bodis; M Pruschy Journal: Cancer Res Date: 2001-01-15 Impact factor: 12.701
Authors: J A Koutcher; M Motwani; K L Zakian; X K Li; C Matei; J P Dyke; D Ballon; H H Yoo; G K Schwartz Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531
Authors: W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson Journal: N Engl J Med Date: 1996-01-04 Impact factor: 91.245
Authors: J Prendiville; D Crowther; N Thatcher; P J Woll; B W Fox; A McGown; N Testa; P Stern; R McDermott; M Potter Journal: Br J Cancer Date: 1993-08 Impact factor: 7.640
Authors: Lydia Usha; Michael W Sill; Kathleen M Darcy; Doris M Benbrook; Jean A Hurteau; David P Michelin; Robert S Mannel; Parviz Hanjani; Koen De Geest; Andrew K Godwin Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482